

Format for ANSWERING REVIEWERS



July 12, 2015

Dear Editor,

Please find enclosed the edited manuscript in Word format (file name: 20300-Review.doc).

Title: Current status of high on-treatment platelet reactivity in patients with coronary or peripheral arterial disease: Mechanisms, evaluation and clinical implications

Author: Stavros Spiliopoulos, Georgios Pastromas

Name of Journal: *World Journal of Cardiology*

ESPS Manuscript NO: 20300

The manuscript has been improved according to the suggestions of reviewers:

Reviewer: 3

Comments to the Authors

This is a comprehensive and useful review describing the current status and addressing briefly the future perspectives of antiplatelet therapy in coronary artery disease as well as peripheral artery disease.

References should be stated according to the requirements of the WJC.

Minor errors:

Page 4: line 17: should "HPR" be HTPR?

Page 4: line 18: "in clinical research" should be deleted. It is mentioned twice.

Page 11: line 11: "CLI" this abbreviation should be clarified.

Page 11: line 13: "been" has been cited twice.

Page 12: line 20: one "(" bracket is missing.

Authors' response. All the above-mentioned errors were corrected according to the reviewer's remarks.

Reviewer: 4

Comments to the Authors

This review paper deals with platelet reactivity during treatment with anti-platelets agents in patients with coronary or peripheral artery disease, focusing on how to measure the platelet reactivity and how to guide therapy based on platelet reactivity. There are some issues which require revision.

1.The title is not very attractive and it is not indicative of what is the main focus of the paper. I suggest to modify it to improve it.

Authors' response. The authors modified the title as follows: “Current Status of High On-Treatment Platelet Reactivity in Patients with Coronary or Peripheral Arterial Disease. Mechanisms, Evaluation and Clinical Implications.”

2.The authors should proofread the whole paper to eliminate some typo or grammatical errors: “clinical research” is written twice on page 4; “has been also been” on page 11; “such as prasugrel and ticagrelor” and “stent thrombosis” is repeated twice on page 12.

Authors' response. All the above-mentioned errors were corrected according to the reviewer's remarks.

3.The second part of the paragraph “Novel antiplatelet agents and PTF-guided antiplatelet therapy” which focuses on studies on “individualized” anti-platelet therapy should stay as a separate paragraph; a table of these data could improve readability and some speculation by the authors will be appreciated.

Authors' response.

The authors added a separate paragraph for PTF-guided antiplatelet therapy and an appropriate comment in lines as follows: “The authors speculate that individualized therapy using PTF as to identify CAD or PAD patients on increased ischemic or bleeding risk, will gradually earn its way in everyday clinical practice as long as future well-designed large-scale trials demonstrate its utility. Novel antiplatelet agents should be prescribed with consciousness as they have been related with increased bleeding events.”

Also the following table was submitted.

Study		GRAVITAS	ARCTIC	TRIGGER-PCI
n	(study population)	2,214	2,440	423
PFT assay		VerifyNow	VerifyNow	VerifyNow
High-dose		100%	80%	–

clopidogrel				
High-dose ASA	–	45%		–
Prasugrel	–	12%		100%
Results (primary endpoint)	2,3 % vs 2,3 %	31,1% 34,6%	vs	0,0% vs 0,5%

Table 2. Highlighted multicenter randomized control trials investigating PFT-guided antiplatelet therapy

4.The authors should comply with the editorial rules for the first page, manuscript, and references

5.The paragraph “genetic factors” and “clinical factors” are sub-paragraphs of “HTPR mechanisms” and they should identified so.

Authors’ response. All the above-mentioned errors were corrected according to the reviewer’s remarks.

Yours sincerely,

Dr. Stavros Spiliopoulos, MD, PhD, EBIR